BiotechTube

Infigratinib

Phase 1/2Withdrawn
0 watching 0 views this week💤 Quiet
38
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Advanced Solid Tumor

Conditions

Advanced Solid Tumor, CNS Tumor, Recurrent WHO Grade II Glioma

Trial Timeline

Oct 1, 2021 → Dec 16, 2022

NCT ID
NCT05222165

About Infigratinib

Infigratinib is a phase 1/2 stage product being developed by LabCorp for Advanced Solid Tumor. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05222165. Target conditions include Advanced Solid Tumor, CNS Tumor, Recurrent WHO Grade II Glioma.

Hype Score Breakdown

Clinical
13
Activity
8
Company
7
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT05222165Phase 1/2Withdrawn

Competing Products

20 competing products in Advanced Solid Tumor

See all competitors
ProductCompanyStageHype Score
AK-105AkesoPhase 1
32
AFM24 + Atezolizumab 840 MG in 14 ML InjectionAffimedPhase 1/2
33
EXS21546BiotrialPhase 1/2
33
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)Syros PharmaceuticalsPhase 1
25
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
52
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
52
NBTXR3NanobiotixPhase 1/2
36
pegfilgrastim + LY2523355Eli LillyPhase 1
33
SON-1010Sonnet BioTherapeuticsPhase 1
28
SON-1010Sonnet BioTherapeuticsPhase 1/2
36
BT1718Bicycle TherapeuticsPhase 1/2
33
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
44
IMC-18F1Eli LillyPhase 1
33
Tadalafil + GemcitabineEli LillyPhase 1
33
OKI-179OnKure TherapeuticsPhase 1
25
OKI-219 + Fulvestrant + Trastuzumab + Tucatinib + Atirmociclib + RibociclibOnKure TherapeuticsPhase 1
25
LY3499446 + Abemaciclib + Cetuximab + Erlotinib + DocetaxelEli LillyPhase 1/2
41
LY3434172Eli LillyPhase 1
33
ACR-2316Acrivon TherapeuticsPhase 1
25
BBP-398LianBioPhase 1
25

Other Products from LabCorp

VIT-2763 60 mg QD + VIT-2763 60 mg BID + VIT-2763 120 mg BID + PlaceboPhase 2
49
VIT-2763 once a day (QD) + VIT-2763 twice a day (BID) + PlaceboPhase 2
49
EMB-01Phase 1/2
38
EMB-01 + OsimertinibPhase 1/2
38
NM8074 + PlaceboPhase 1
30